JP7745571B2 - 肺線維症を処置する方法 - Google Patents

肺線維症を処置する方法

Info

Publication number
JP7745571B2
JP7745571B2 JP2022572568A JP2022572568A JP7745571B2 JP 7745571 B2 JP7745571 B2 JP 7745571B2 JP 2022572568 A JP2022572568 A JP 2022572568A JP 2022572568 A JP2022572568 A JP 2022572568A JP 7745571 B2 JP7745571 B2 JP 7745571B2
Authority
JP
Japan
Prior art keywords
pulmonary fibrosis
formula
acid
compound
idiopathic pulmonary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022572568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527358A5 (https=
JP2023527358A (ja
Inventor
クリス バーンズ，
ジョン ランバート，
マーク グレーム デブリン，
Original Assignee
アンプリア セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901743A external-priority patent/AU2020901743A0/en
Application filed by アンプリア セラピューティクス リミテッド filed Critical アンプリア セラピューティクス リミテッド
Publication of JP2023527358A publication Critical patent/JP2023527358A/ja
Publication of JP2023527358A5 publication Critical patent/JP2023527358A5/ja
Application granted granted Critical
Publication of JP7745571B2 publication Critical patent/JP7745571B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022572568A 2020-05-28 2021-05-17 肺線維症を処置する方法 Active JP7745571B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020901743 2020-05-28
AU2020901743A AU2020901743A0 (en) 2020-05-28 Methods of treating pulmonary fibrosis
PCT/AU2021/050457 WO2021237273A1 (en) 2020-05-28 2021-05-17 Methods of treating pulmonary fibrosis

Publications (3)

Publication Number Publication Date
JP2023527358A JP2023527358A (ja) 2023-06-28
JP2023527358A5 JP2023527358A5 (https=) 2024-05-14
JP7745571B2 true JP7745571B2 (ja) 2025-09-29

Family

ID=78745664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572568A Active JP7745571B2 (ja) 2020-05-28 2021-05-17 肺線維症を処置する方法

Country Status (9)

Country Link
US (1) US20230190746A1 (https=)
EP (1) EP4157278A4 (https=)
JP (1) JP7745571B2 (https=)
KR (1) KR20230017843A (https=)
CN (1) CN115867281A (https=)
AU (1) AU2021279205B2 (https=)
CA (1) CA3177652A1 (https=)
NZ (1) NZ793855A (https=)
WO (1) WO2021237273A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3001119T3 (es) 2019-03-28 2025-03-04 Amplia Therapeutics Ltd Una sal y forma cristalina de un inhibidor de FAK
WO2023139154A1 (en) * 2022-01-19 2023-07-27 Nordic Bioscience A/S A method for detecting covid-19 in a patient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9174946B2 (en) * 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
WO2014027199A1 (en) * 2012-08-14 2014-02-20 Cancer Therapeutics Crc Pty Ltd Fak and flt3 inhibitors
ES3001119T3 (es) * 2019-03-28 2025-03-04 Amplia Therapeutics Ltd Una sal y forma cristalina de un inhibidor de FAK

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Joana Carvalho，FDA Names AMP945, Potential IPF Treatment, an Orphan Drug，online，2020年05月20日，URL: https://pulmonaryfibrosisnews.com/news/fda-names-amp945-potential-idiopathic-pf-treatment-orphan-drug/
Peter M GEORGE et al.，"Pulmonary fibrosisand COVID-19: the potential role for antifibrotic therapy"，The Lancet Respiratory Medicine，2020年05月15日，Vol. 8, No. 8，p.807-815，DOI: 10.1016/S2213-2600(20)30225-3

Also Published As

Publication number Publication date
US20230190746A1 (en) 2023-06-22
WO2021237273A1 (en) 2021-12-02
KR20230017843A (ko) 2023-02-06
NZ793855A (en) 2026-02-27
CN115867281A (zh) 2023-03-28
EP4157278A4 (en) 2024-07-03
EP4157278A1 (en) 2023-04-05
AU2021279205A1 (en) 2022-12-08
JP2023527358A (ja) 2023-06-28
AU2021279205B2 (en) 2025-12-04
CA3177652A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
US20220152057A1 (en) Methods and compositions for treating various disorders
AU2018357775B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
JP6827948B2 (ja) 呼吸器疾患の治療
EP3551187B1 (en) Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
HUP0204079A2 (hu) Szedatív hatástól mentes antihisztaminok és leukotrién hatást befolyásoló anyagok új kombinációja orrnyálkahártya-gyulladás, vagy kötőhártya-gyulladás kezelésére
US20100093754A1 (en) Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual Disorders
JP2010514696A (ja) 心血管症状の低減
JP2009526829A (ja) 流涎症の治療のためのアルファ−２受容体アゴニスト（クロニジン）と抗ムスカリン剤（オキシブチニン）との組み合わせ
JP7745571B2 (ja) 肺線維症を処置する方法
US20130079304A1 (en) Pharmaceutical Compositions for the Treatment of Fungal Infections
AU2025271047A1 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JP2010533166A (ja) シロスタゾールを含むカルボスチリル誘導体の脂肪肝治療剤
CN100418526C (zh) 依贝沙坦在制备用来预防或治疗肺动脉高压的药物中的应用
US8648100B2 (en) Roflumilast for the treatment of pulmonary hypertension
FI4199922T3 (fi) (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa
JP6051315B2 (ja) 乾癬を処置するためのピドチモドの使用
RU2809024C2 (ru) Монтелукаст для лечения эрозивного остеоартрита кистей рук
CN119522109A (zh) 用于钙调磷酸酶抑制剂的间歇性给药的组合物
WO2003047591A1 (fr) Medicaments contre l'hypertension arterielle pulmonaire primitive
JP2026510948A (ja) 慢性閉塞性肺疾患患者におけるエンテロウイルスの治療方法
HK40054679A (en) Montelukast for the treatment of erosive hand osteoarthritis
HK40054679B (en) Montelukast for the treatment of erosive hand osteoarthritis
HK1221913B (zh) Par-1拮抗剂用於预防和/或治疗骨盆-会阴功能病状的用途
JP2000290198A (ja) 鼻腔抵抗上昇等の抑制剤
EP0998923A1 (en) Use of 5-HT7 receptor agonists for the treatment or prophylaxis of ischemias

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250527

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250821

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250916

R150 Certificate of patent or registration of utility model

Ref document number: 7745571

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150